[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562208":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":65,"collaborators":26,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":26,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Drug Group","EXPERIMENTAL","Brezavvy 20mg oral tablet",[13],"Drug: Brezavvy 20Mg Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","placebo tablet",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Brezavvy 20Mg Oral Tablet","Brezavvy 20mg oral",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo tablet given to subject vs. active drug.",[15],[32],{"name":33,"affiliation":34,"role":35},"Patricia Rodriguez-Lozano, MD","Uni","PRINCIPAL_INVESTIGATOR",[37,41],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","434-982-1058","PR3GG@uvahealth.org",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Shuo Wang","4349821058","VJR7CE@uvahealth.org",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"UVA Health","RECRUITING","Charlottesville","Virginia","22908","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-78.47668,38.02931,{"lat":58,"lon":57},[61,62],{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},{"name":63,"role":38,"phone":39,"phoneExt":26,"email":64},"Nicole Sprouse, RN","njb6m@uvahealth.org",{"type":35,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Patricia Rodriguez Lozano","Principal Investigator","100562208","phase-1-study-targeting-myocardial-perfusion-and-symptom-relief-in-women-with-sglt2-inhibitors-strong-100562208",false,"NCT06600178","Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)","Innovative Therapy to Treat Women With Angina With Nonobstructive Coronary Artery Disease (ANOCA) and Coronary Microvascular Disease","STRONG","Inclusion Criteria:\n\n* • Female sex.\n\n  * Age ≥18 years.\n  * Willing and able to provide written informed consent.\n  * Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.\n  * No evidence of obstructive epicardial CAD (stenosis \\\u003C50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.\n  * Diagnosis of CMD defined by CFR \\< 2 by CMR\n  * Never on SGLT2i\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy LVEF \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of acute coronary syndrome (ACS) within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP \\>95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent UTI\u002Fbladder\u002Fkidney infections\n* Asthma with ongoing wheezing\n* Known or suspected broncho-constrictive or bronchospastic lung disease (ARDS, emphysema)\n* Greater than first degree heart block\n* Implanted cardiac device\n* Profound sinus bradycardia (heart rate \\\u003C40 beats per minute)\n* Atrial fibrillation or supraventricular arrhythmias at time of imaging\n* Known intolerance of nitrates (other than hypotension)\n* History of reaction to iodinated contrast agents","FEMALE","18 Years",{"count":79,"type":80},150,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are:\n\nAim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease.\n\nAim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR.\n\nAIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo\n\nParticipants will:\n\n* Take study drug or placebo for 12 weeks\n* Stress Cardiac magnetic resonance imaging\n* 12 lead electrocardiograms\n* Complete questionnaires",[86,87,88],"Angina Patients With Non-obstructive Coronary Artery Disease","Coronary Microvascular Disease","Coronary Microvascular Dysfunction (CMD)",[90,91,92,93,94,95],"Angina","ANOCA","Non-obstructive Coronary Artery Disease","CMD","Non-Obstructive CAD","Chest Pain in Women","2025-10-27",{"date":98,"type":99},"2025-10-29","ACTUAL",{"date":101,"type":99},"2025-06-27",{"date":103,"type":80},"2026-10",{"name":5,"class":6},1]